DK3500664T3 - Fremgangsmåde til differentiering af pluripotente celler - Google Patents
Fremgangsmåde til differentiering af pluripotente celler Download PDFInfo
- Publication number
- DK3500664T3 DK3500664T3 DK17758363.0T DK17758363T DK3500664T3 DK 3500664 T3 DK3500664 T3 DK 3500664T3 DK 17758363 T DK17758363 T DK 17758363T DK 3500664 T3 DK3500664 T3 DK 3500664T3
- Authority
- DK
- Denmark
- Prior art keywords
- pluripotent cells
- differentiating pluripotent
- differentiating
- cells
- pluripotent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/80—Hyaluronan
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662375590P | 2016-08-16 | 2016-08-16 | |
PCT/US2017/047124 WO2018035214A1 (en) | 2016-08-16 | 2017-08-16 | Methods for differentiating pluripotent cells |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3500664T3 true DK3500664T3 (da) | 2021-12-06 |
Family
ID=59714142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17758363.0T DK3500664T3 (da) | 2016-08-16 | 2017-08-16 | Fremgangsmåde til differentiering af pluripotente celler |
Country Status (10)
Country | Link |
---|---|
US (2) | US10590383B2 (da) |
EP (3) | EP3500664B1 (da) |
JP (2) | JP7120993B2 (da) |
KR (2) | KR102487142B1 (da) |
CN (2) | CN109844102B (da) |
AU (2) | AU2017313065B2 (da) |
CA (1) | CA3033205A1 (da) |
DK (1) | DK3500664T3 (da) |
ES (1) | ES2901379T3 (da) |
WO (1) | WO2018035214A1 (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018140647A1 (en) | 2017-01-25 | 2018-08-02 | Cedars-Sinai Medical Center | In vitro induction of mammary-like differentiation from human pluripotent stem cells |
US11767513B2 (en) | 2017-03-14 | 2023-09-26 | Cedars-Sinai Medical Center | Neuromuscular junction |
JP2021516545A (ja) * | 2018-03-07 | 2021-07-08 | ソルボンヌ、ユニベルシテSorbonne Universite | 網膜始原細胞の効率的増幅のための組成物及び方法 |
CN108456659B (zh) * | 2018-03-14 | 2020-05-05 | 浙江霍德生物工程有限公司 | 3d大脑类器官的制备方法 |
US11981918B2 (en) | 2018-04-06 | 2024-05-14 | Cedars-Sinai Medical Center | Differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells |
US20210033628A1 (en) | 2018-04-30 | 2021-02-04 | Cedars-Sinai Medical Center | Diagnostic and drug screening for molecular signatures of early onset sporadic parkinson's disease |
EP3972617A4 (en) * | 2019-05-23 | 2023-06-07 | The McLean Hospital Corporation | AUTOLOGOUS CELLULAR SUBSTITUTION THERAPY FOR PARKINSON'S DISEASE |
MX2022002532A (es) * | 2019-08-29 | 2022-06-16 | Memorial Sloan Kettering Cancer Center | Métodos para generar y aislar neuronas de dopamina del mesencéfalo. |
KR102288424B1 (ko) * | 2019-09-20 | 2021-08-11 | 한국생명공학연구원 | 직접 리프로그래밍을 통한 유도 도파민성 신경세포 전구체의 제조방법 |
MX2022011831A (es) | 2020-03-25 | 2023-01-04 | Sana Biotechnology Inc | Células neurales hipoinmunogénicas para el tratamiento de trastornos y afecciones neurológicas. |
WO2021263241A1 (en) * | 2020-06-26 | 2021-12-30 | Minerva Biotechnologies Corporation | Methods for deriving dopaminergic neurons from pluripotent stem cells |
CN116635047A (zh) * | 2020-06-26 | 2023-08-22 | 米纳瓦生物技术公司 | 用于从多能干细胞衍生多巴胺能神经元的方法 |
US20230323293A1 (en) * | 2020-08-17 | 2023-10-12 | Institute Of Zoology, Chinese Academy Of Sciences | Expansion culture medium and culture method for neural cells |
CN114292814A (zh) * | 2020-09-22 | 2022-04-08 | 上海跃赛生物科技有限公司 | 一种多能干细胞分化为中脑黒质多巴胺能神经细胞的方法 |
TWI808661B (zh) | 2021-03-05 | 2023-07-11 | 日商旭化成股份有限公司 | 氧化還原液流電池用電極及氧化還原液流電池用電極之製造方法 |
AU2022256048A1 (en) | 2021-04-07 | 2023-10-05 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic precursor cells and methods of use |
CN115873797A (zh) * | 2021-09-29 | 2023-03-31 | 北京干细胞与再生医学研究院 | 一种视网膜色素上皮细胞的扩增培养基及培养方法 |
WO2024085215A1 (ja) * | 2022-10-20 | 2024-04-25 | 株式会社ケイファーマ | 神経幹細胞/神経前駆細胞の新規製造方法 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
WO1998030679A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
US20020168766A1 (en) | 2000-01-11 | 2002-11-14 | Gold Joseph D. | Genetically altered human pluripotent stem cells |
EP1302533A4 (en) | 2000-05-16 | 2004-11-17 | Kyowa Hakko Kogyo Kk | NEW METHOD FOR INDUCING DIFFERENTIATION OF EMBRYONIC STEM CELLS IN EECTODERMAL CELLS AND THEIR USE |
WO2001088104A2 (en) | 2000-05-17 | 2001-11-22 | Geron Corporation | Neural progenitor cell populations |
ES2280517T3 (es) | 2001-03-23 | 2007-09-16 | Bayer Pharmaceuticals Corporation | Inhibidor de rho-cinasa. |
PT1370553E (pt) | 2001-03-23 | 2006-09-29 | Bayer Corp | Inibidores de rhoquinase |
JP2004535199A (ja) | 2001-07-12 | 2004-11-25 | ジェロン コーポレイション | ヒト多能性幹細胞から産生される心筋細胞系譜の細胞 |
US20030211603A1 (en) | 2001-08-14 | 2003-11-13 | Earp David J. | Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells |
DE60320933D1 (de) | 2002-01-10 | 2008-06-26 | Bayer Healthcare Ag | Rho-kinase inhibitoren |
WO2003062225A1 (en) | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
JP4423043B2 (ja) | 2002-01-23 | 2010-03-03 | バイエル ファーマセチカル コーポレーション | Rho−キナーゼ阻害剤 |
AU2003278088A1 (en) | 2002-10-28 | 2004-05-25 | Bayer Healthcare Ag | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors |
WO2005080554A1 (ja) | 2004-02-23 | 2005-09-01 | Kyoto University | 胚性幹細胞の分化調節方法 |
WO2005123902A1 (ja) | 2004-06-18 | 2005-12-29 | Riken | 無血清浮遊培養による胚性幹細胞の神経分化誘導法 |
US7442548B2 (en) | 2004-09-08 | 2008-10-28 | Wisconsin Alumni Research Foundation | Culturing human embryonic stem cells in medium containing pipecholic acid and gamma amino butyric acid |
US20070116680A1 (en) | 2005-11-18 | 2007-05-24 | Rensselaer Polytechnic Institute | Stem cells within gel microenvironments |
GB2458863B (en) | 2007-01-17 | 2011-10-12 | Wisconsin Alumni Res Found | Improved culture of stem cells |
ES2587395T3 (es) | 2008-06-04 | 2016-10-24 | Cellular Dynamics International, Inc. | Procedimientos para la producción de células IPS usando un enfoque no vírico |
EP2356218B1 (en) | 2008-12-05 | 2017-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and medium for neural differentiation of pluripotent cells |
WO2010096496A2 (en) * | 2009-02-17 | 2010-08-26 | Memorial Sloan-Kettering Cancer Center | Methods of neural conversion of human embryonic stem cells |
EP2548950B1 (en) | 2009-06-05 | 2017-10-25 | Cellular Dynamics International, Inc. | Reprogramming T cells and hematopoietic cells |
CA2831609C (en) | 2011-03-30 | 2019-06-11 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
WO2013067362A1 (en) * | 2011-11-04 | 2013-05-10 | Memorial Sloan-Kettering Cancer Center | Midbrain dopamine (da) neurons for engraftment |
EP3031908B1 (en) | 2013-08-06 | 2018-12-05 | Takeda Pharmaceutical Company Limited | Method for producing dopaminergic neurons |
KR20230008892A (ko) * | 2013-11-21 | 2023-01-16 | 메모리얼 슬로안 케터링 캔서 센터 | 인간 다능성 줄기 세포로부터 기능적 두개 기원판 유도체의 전문화 |
ES2939807T3 (es) * | 2014-03-21 | 2023-04-27 | Fujifilm Cellular Dynamics Inc | Producción de neuronas dopaminérgicas del mesencéfalo y métodos para su utilización |
US9830679B2 (en) | 2014-03-25 | 2017-11-28 | Google Llc | Shared virtual reality |
EP4070803A1 (en) | 2015-06-01 | 2022-10-12 | Memorial Sloan-Kettering Cancer Center | Methods of in vitro differentiation of midbrain dopamine (mda) neurons |
-
2017
- 2017-08-16 AU AU2017313065A patent/AU2017313065B2/en active Active
- 2017-08-16 US US15/678,432 patent/US10590383B2/en active Active
- 2017-08-16 KR KR1020197007694A patent/KR102487142B1/ko active IP Right Grant
- 2017-08-16 CN CN201780063703.0A patent/CN109844102B/zh active Active
- 2017-08-16 DK DK17758363.0T patent/DK3500664T3/da active
- 2017-08-16 CN CN202311347195.2A patent/CN117467608A/zh active Pending
- 2017-08-16 EP EP17758363.0A patent/EP3500664B1/en active Active
- 2017-08-16 EP EP21197831.7A patent/EP4001403A1/en active Pending
- 2017-08-16 KR KR1020227020165A patent/KR102625865B1/ko active IP Right Grant
- 2017-08-16 JP JP2019508965A patent/JP7120993B2/ja active Active
- 2017-08-16 EP EP23202144.4A patent/EP4328301A2/en active Pending
- 2017-08-16 CA CA3033205A patent/CA3033205A1/en active Pending
- 2017-08-16 WO PCT/US2017/047124 patent/WO2018035214A1/en unknown
- 2017-08-16 ES ES17758363T patent/ES2901379T3/es active Active
-
2020
- 2020-02-05 US US16/782,772 patent/US20200172862A1/en active Pending
-
2021
- 2021-09-01 AU AU2021225187A patent/AU2021225187B2/en active Active
-
2022
- 2022-03-09 JP JP2022035753A patent/JP2022078245A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4001403A1 (en) | 2022-05-25 |
US20200172862A1 (en) | 2020-06-04 |
KR102487142B1 (ko) | 2023-01-12 |
US10590383B2 (en) | 2020-03-17 |
CN117467608A (zh) | 2024-01-30 |
CN109844102B (zh) | 2023-11-10 |
AU2017313065A1 (en) | 2019-02-28 |
KR102625865B1 (ko) | 2024-01-16 |
WO2018035214A8 (en) | 2018-05-03 |
US20180051248A1 (en) | 2018-02-22 |
JP7120993B2 (ja) | 2022-08-17 |
KR20220088800A (ko) | 2022-06-28 |
AU2021225187A1 (en) | 2021-09-30 |
KR20190039434A (ko) | 2019-04-11 |
CA3033205A1 (en) | 2018-02-22 |
EP4328301A2 (en) | 2024-02-28 |
ES2901379T3 (es) | 2022-03-22 |
AU2017313065B2 (en) | 2021-06-24 |
CN109844102A (zh) | 2019-06-04 |
WO2018035214A1 (en) | 2018-02-22 |
EP3500664A1 (en) | 2019-06-26 |
JP2019531062A (ja) | 2019-10-31 |
AU2021225187B2 (en) | 2024-01-04 |
EP3500664B1 (en) | 2021-09-22 |
JP2022078245A (ja) | 2022-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3500664T3 (da) | Fremgangsmåde til differentiering af pluripotente celler | |
DK3444334T3 (da) | Fremgangsmåde til inducering af CD8+ T-celler | |
DK3116902T3 (da) | Fremgangsmåde til generering af T-celler kompatible for allogen transplantation | |
DK3186376T3 (da) | Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet | |
DK3292134T3 (da) | Metode til dyrkning af akkermansia | |
DK3316703T3 (da) | Fremgangsmåde til forbedring af dyrs ydeevne | |
DK3512959T3 (da) | Fremgangsmåder til udførelse af multipleks PCR | |
DK3122444T3 (da) | Fremgangsmåde til fremstilling af membraner | |
DK3110988T3 (da) | Metoder til behandling af lithiumholdige materialer | |
DK3294700T3 (da) | Fremgangsmåde til fremstilling af limonen-4-ol | |
DK3140393T3 (da) | Fremstillingsmetode for voksne leverstamceller | |
DK3247201T3 (da) | Fremgangsmåder til opgradering af brugt biomassemateriale | |
DK3285784T3 (da) | Fremgangsmåde til fremstilling af en prøve af fækal mikrobiota | |
DK3359281T3 (da) | Fremgangsmåde til udtrækning af CO2 | |
DK2966044T3 (da) | Fremgangsmåde til fremstilling af skumglas | |
DK3529233T3 (da) | Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider | |
DK3580330T3 (da) | Fremgangsmåde til generering af t-celleprogenitorer | |
DK3166927T3 (da) | Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxy-picolinsyre | |
DK3365436T3 (da) | Fremgangsmåder til fremstilling af en primær celleprøve | |
HUE056016T2 (hu) | Módszerek a T-sejtek válaszának elõsegítésére | |
DK3253906T3 (da) | Elektrolyt til elektroplettering | |
DK3347481T3 (da) | Fremgangsmåde til oprensning af biomassehydrolysat | |
DK3384045T3 (da) | Fremgangsmåde til bestemmelse af celleklonalitet | |
DK3331986T3 (da) | Fremgangsmåde til fremstilling af celledyrkningsmedium | |
DK3622081T3 (da) | Fremgangsmåde til fremstilling af en azaphilon i talaromyces atroroseus |